EPSTEIN–BARR VIRUS IN THE POPULATION OF TWO GEOGRAPHICALLY DIFFERENT REGIONS OF RUSSIA

Cover Page

Cite item

Abstract

It is well known that the Epstein–Barr virus (EBV) being widely spread in the human population is also the etiologic agent for a number of malignancies. A notable feature of tumors associated with EBV is their different incidence in various geographical regions, that, as suggested, related with mutational events in multiple loci of the EBV genome and its oncogene, the latent membrane protein 1 (LMP1), associated with the transforming potential of the virus. Given the multi-ethnic composition of Russian population and the diversity of geographical areas and conditions of their residence, it was relevant to examine the representatives of different geographical regions for the nature of their relationship with EBV. To solve this task the antibody response to locally circulating EBV strains, determined by indirect immunofluorescence, was studied in residents of the Central, North Caucasus and Far Eastern Federal Districts, represented by healthy individuals and patients with various head and neck tumors. The levels of antibody titers obtained were compared with the incidence rates of nasopharyngeal tumors (NPT) in population of above Districts. In order to determine possible structural modifications in LMP1 gene of EBV strains persisting in selected geographic regions, samples of the gene have been amplified from a biological material collected by “nested” PCR and sequenced. The results obtained have shown that levels of antibody response to EBV among representatives of the regions included in the study vary significantly. It was found that in residents of the Dagestan and the Chechen Republics, the inhabitants of the North Caucasus Federal District, the correlation between enhanced humoral response to EBV and increased incidence of NPT was detected. Since among NPT the EBV-associated form of nasopharyngeal carcinoma (NPCEBV) is dominated, the findings allow us to suggest that the population of these Republics have genetic predisposition to increased EBV replication and, consequently, an elevated incidence of NPCEBV. The study also showed that representatives of the regions tested are infected with EBV strains, LMP1 variants of which such as B95.8, China 1, Med+, Med– and NC, are known in the literature. However, LMP1 variant, specifically associated with NPCEBV, has not been identified. This study showed for the first time the genetic heterogeneity of EBV strains circulating among population of different geographical regions of the country, and the existence of correlation between antibody response to EBV and the incidence of nasopharyngeal tumors, including NPCEBV.

About the authors

N. B. Senyuta

N.N. Blokhin Russian Cancer Research Center, Ministry of Health

Email: fake@neicon.ru

PhD (Medicine), Leading Researcher, Laboratory of Viral Carcinogenesis

Russian Federation

A. V. Ignatova

N.N. Blokhin Russian Cancer Research Center, Ministry of Health

Email: fake@neicon.ru

PhD Candidate, Department of The Tumors of Respiratory and Digestive Tract

Russian Federation

M. V. Lomaya

N.N. Blokhin Russian Cancer Research Center, Ministry of Health

Email: fake@neicon.ru

PhD Candidate, Department of the Head and Neck Tumors

Russian Federation

E. V. Goncharova

N.N. Blokhin Russian Cancer Research Center, Ministry of Health

Email: fake@neicon.ru

PhD (Biology), Senior Researcher, Laboratory of Viral Carcinogenesis

Russian Federation

L. N. Scherback

N.N. Blokhin Russian Cancer Research Center, Ministry of Health

Email: fake@neicon.ru

PhD (Biology), Researcher, Laboratory of Viral Carcinogenesis

Russian Federation

T. E. Dushenkina

N.N. Blokhin Russian Cancer Research Center, Ministry of Health

Email: fake@neicon.ru

Investigator (Biologist), Laboratory of Viral Carcinogenesis

Russian Federation

D. V. Gugunov

N.N. Blokhin Russian Cancer Research Center, Ministry of Health

Email: fake@neicon.ru
PhD (Biology), Oncologist, Outpatient Department Russian Federation

A. M. Mudunov

N.N. Blokhin Russian Cancer Research Center, Ministry of Health

Email: fake@neicon.ru

PhD, MD (Medicine), Head of the Department of Respiratory and Digestive Tract Tumors

Russian Federation

V. E. Gurtsevitch

N.N. Blokhin Russian Cancer Research Center, Ministry of Health

Author for correspondence.
Email: gurtsevitch-vlad-88@yandex.ru

PhD, MD (Medicine), Professor, Head of the Laboratory of Viral Carcinogenesis

115478, Russia, Moscow, Kashirskoye highway, 24, Phone: +7 (499) 324-25-64 (office); +7 910 444-83-52 (mobile). Fax: +7 (499) 324-12-05

Russian Federation

References

  1. Blake S.M., Eliopoulos A.G., Dawson C.W., Young L.S. The transmembrane domains of the EBV-encoded latent membrane protein 1 (LMP1) variant CAO regulate enhanced signalling activity. Virology, 2001, vol. 282, no. 2, pp. 278–287. doi: 10.1006/viro.2001.0828
  2. De-The G., Lavoue M.F., Muenz L. Differences in EBV antibody titres of patients with nasopharyngeal carcinoma originating from high, intermediate and low incidence. IARC Sci. Publ. 1978, vol. 20, pp. 471–481.
  3. Edwards R.H., Seillier-Moiseiwitsch F., Raab-Traub N. Signature amino acid changes in latent membrane protein 1 distinguish Epstein–Barr virus strains. Virology, 1999, vol. 261, no. 1, pp. 79–95. doi: 10.1006/viro.1999.9855
  4. Gratama J.W., Ernberg I. Molecular epidemiology of Epstein–Barr virus infection. Adv. Cancer Res., 1995, vol. 67, pp. 197–255.
  5. Guo L., Tang M., Yang L., Xiao L., Bode A.M., Li L., Dong Z., Cao Y. Epstein–Barr virus oncoprotein LMP1 mediates survivin upregulation by p53 contributing to G1/S cell cycle progression in nasopharyngeal carcinoma. Int. J. Mol. Med., 2012, vol. 29, no. 4, pp. 574–580. doi: 10.3892/ijmm.2012.889
  6. Gurtsevitch V.E., Iakovleva L.S., Shcherbak L.N. Goncharova E.V., Smirnova K.V., Diduk S.V., Kondratova V.N., Maksimovich D.M., Lichtenstein A.V., Senyuta N.B. The LMP1 oncogene sequence variations in patients with oral tumours associated or not associated with the Epstein–Barr virus. Mol. Biol. (Mosk.), 2013, vol. 47, no. 6, pp. 987–995.
  7. Gurtsevitch V., Ruiz R., Stepina V., Plachov I., Le Riverend E., Glazkova T., Lavoué M.F., Paches A., Aliev B., Mazurenko N. Epstein–Barr viral serology in nasopharyngeal carcinoma patients in the USSR and Cuba, and its value for differential diagnosis of the disease. Int. J. Cancer, 1986, vol. 37, no. 3, pp. 375–381.
  8. Hahn P., Novikova E., Scherback L., Janik C., Pavlish O., Arkhipov V., Nicholls J., Müller-Lantzsch N., Gurtsevitch V., Grässer F.A. The LMP1 gene isolated from Russian nasopharyngeal carcinoma has no 30-bp deletion. Int. J. Cancer, 2001, vol. 91, no. 6, pp. 815–821.
  9. Horikawa T., Yoshizaki T., Kondo S., Furukawa M,. Kaizaki Y., Pagano J.S. Epstein–Barr virus latent membrane protein 1 induces Snail and epithelial-mesenchymal transition in metastatic nasopharyngeal carcinoma. Br. J. Cancer, 2011, vol. 104, no. 7, pp. 1160–1167. doi: 10.1038/bjc.2011.38
  10. Ji M.F., Yu Y.L., Cheng W.M., Zong Y.S., Ng P.S., Chua D.T., Ng M.H. Detection of stage I nasopharyngeal carcinoma by serologic screening and clinical examination. Chin J. Cancer, 2011, vol. 30, no. 2, pp. 120–123.
  11. Johnson R.J., Stack M., Hazlewood S.A., Jones M., Blackmore C.G., Hu L.F., Rowe M. The 30-base-pair deletion in Chinese variants of the Epstein–Barr virus LMP1 gene is not the major effector of functional differences between variant LMP1 genes in human lymphocytes. J. Virol., 1998, vol. 72, no. 5, pp. 4038–4048.
  12. Lung M.L., Chang G.C. Detection of distinct Epstein–Barr virus genotypes in NPC biopsies from southern Chinese and Caucasians. Int. J. Cancer, 1992, vol. 52, no. 1, pp. 34–37.
  13. Lung M.L., Lam W.P., Sham J., Choy D., Yong Sheng Z., Guo H.Y., Ng M.H. Detection and prevalence of the «f» variant of Epstein–Barr virus in southern China. Virology, 1991, vol. 185, no. 1, pp. 67–71.
  14. Man C., Rosa J., Lee L.T., Lee V.H., Chow B.K., Lo K.W., Doxsey S., Wu Z.G., Kwong Y.L., Jin D.Y., Cheung A.L., Tsao S.W. Latent membrane protein 1 suppresses RASSF1A expression, disrupts microtubule structures and induces chromosomal aberrations in human epithelial cells. Oncogene, 2007, vol. 26, no. 21, pp. 3069–3080. doi: 10.1038/sj.onc.1210106
  15. Nitta T., Chiba A., Yamamoto N., Yamaoka S. Lack of cytotoxic property in a variant of Epstein–Barr virus latent membrane protein-1 isolated from nasopharyngeal carcinoma. Cell Signal, 2004, vol. 16, no. 9, pp. 1071–1081. doi: 10.1016/j.cellsig.2004.03.001
  16. Rickinson A.B., Young L.S., Rowe M. Influence of the Epstein–Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. J. Virol., 1987, vol. 61, no. 5, pp. 1310–1317.
  17. Tierney R.J., Steven N., Young L.S., Rickinson A.B. Epstein–Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J. Virol., 1994, vol. 68, no. 11, pp. 7374–7385.
  18. Tzellos S., Farrell P.J. Epstein–Barr virus sequence variation-biology and disease. Pathogens, 2012, vol. 1, no. 2, pp. 156–174. doi: 10.3390/pathogens1020156
  19. Wang D., Liebowitz D., Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell, 1985, vol. 43, no. 3, pp. 831–840.
  20. Young L.S., Dawson C.W., Eliopoulos A.G. The expression and function of Epstein–Barr virus encoded latent genes. Mol. Pathol., 2000, vol. 53, no. 5, pp. 238–247.
  21. Yu M.C., Yuan J.M. Epidemiology of nasopharyngeal carcinoma. Semin. Cancer Biol. 2002, vol. 12, no. 6, pp. 421–429.
  22. Zhou X.G., Sandvej K., Li P.J., Ji X.L., Yan Q.H., Zhang X.P., Da J.P., Hamilton-Dutoit S.J. Epstein–Barr virus gene polymorphisms in Chinese Hodgkin’s disease cases and healthy donors: identification of three distinct virus variants. J. Gen. Virol., 2001, vol. 82, no. 5, pp. 1157–1167. doi: 10.1099/0022-1317-82-5-1157
  23. Zhu X., Wang Y., Sun Y., Zheng J., Zhu D. MiR-155 up-regulation by LMP1 DNA contributes to increased nasopharyngeal carcinoma cell proliferation and migration. Eur. Arch. Otorhinolaryngol., 2014, vol. 271, no. 7, pp. 1939–1945. doi: 10.1007/s00405-013-2818-0

Copyright (c) 2017 Senyuta N.B., Ignatova A.V., Lomaya M.V., Goncharova E.V., Scherback L.N., Dushenkina T.E., Gugunov D.V., Mudunov A.M., Gurtsevitch V.E.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies